Physician profile
Michael A Cooper
NPI 1831120757
$5,796.89
in general payments reported to CMS, 2019-2025
20 companies · $752 in 2025
The $752 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,369 · 2020: $178 · 2021: $96.71 · 2024: $401 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,153.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi US Services INC. | $3,951.36 | 2019 | |
| Novo Nordisk INC | $406.31 | 2019-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $273.44 | 2020-2025 | |
| Inspire Medical Systems, INC. | $171.03 | 2024-2025 | Inspire |
| Lilly USA, LLC | $158.32 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $146.09 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.21 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $102.12 | 2019-2024 | |
| Exact Sciences Corporation | $87.33 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $79.22 | 2019-2025 | |
| Boston Scientific Corporation | $63.79 | 2025 | Wavewriter Alpha Prime 16 |
| Glaxosmithkline, LLC. | $51.94 | 2025 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $50.98 | 2024 | Breztri, Farxiga |
| Astellas Pharma US INC | $33.93 | 2024 | Veozah |
| Dynavax Technologies Corporation | $32.38 | 2025 | Heplisav-B |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $28.18 | 2019 | |
| Allergan, INC. | $13.86 | 2019 | |
| Ibsa Pharma INC. | $12.45 | 2020 | |
| Sanofi Pasteur INC. | $12.31 | 2019 | |
| Therapeuticsmd, INC. | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.